What is the first-line treatment option for a reproductive-age woman with symptomatic endometriosis?

First-Line Treatment for Symptomatic Endometriosis in Reproductive-Age Women

The first recommended option for a reproductive-age woman with symptomatic endometriosis is hormonal medical therapy, specifically combined oral contraceptives (COCs) used continuously or the 52mg levonorgestrel-releasing intrauterine system (LNG-IUS). 1, 2

Primary Treatment Approach

The most recent 2025 German/Austrian/Swiss guideline explicitly recommends primary hormone treatment as the first-choice approach for symptomatic endometriosis 2. This represents a significant shift toward medical management before considering surgical intervention.

Specific First-Line Options

Combined Oral Contraceptives (COCs):

• Should be used continuously (without pill-free intervals) 3
• Superior to placebo and have comparable efficacy to dienogest 4
• Well-tolerated, inexpensive, and effective for pain control 5

52mg Levonorgestrel-Releasing IUS:

• Equally recommended as first-line alongside COCs 1
• Provides long-term symptom control
• Particularly useful when contraception is also desired

Dienogest:

• Most extensively studied progestin therapy 4
• Strong evidence supporting its use as first-line treatment 4
• Acceptable alternative to COCs

Treatment Algorithm

1. Initial therapy: Start with either continuous COCs or 52mg LNG-IUS based on patient preference and contraceptive needs
2. Alternative first-line: Dienogest if COCs or IUS are contraindicated or not tolerated
3. Duration: Long-term treatment is necessary as these therapies are suppressive, not curative 5
4. Failure of first-line: If symptoms persist despite adequate trial (typically 3-6 months), consider:
   • Switching to alternative first-line hormonal therapy
   • GnRH agonists as second-line treatment 4, 5
   • Surgical consultation for multidisciplinary evaluation 1

Important Clinical Considerations

NSAIDs alone are insufficient: While widely used for dysmenorrhea, there is inconclusive evidence for their efficacy in relieving endometriosis-associated pelvic pain 3. They may be used as adjunctive therapy but should not be the sole treatment.

GnRH agonists are second-line only: These should be reserved for cases where first-line therapies fail, are not tolerated, or are contraindicated 4, 5. They require add-back therapy due to hypoestrogenic side effects and concerns about bone mineral density and cardiovascular health 4.

Surgery is not first-line for symptom control: The 2025 guideline emphasizes that surgical interventions should be supplemented on an individual, symptom-oriented basis rather than as primary therapy 2. Surgery is indicated when pain cannot be controlled with medication or when there is severe disease with multiorgan involvement 1, 6.

Common Pitfalls to Avoid

• Delaying hormonal therapy: Do not wait for surgical diagnosis before initiating treatment in symptomatic patients
• Intermittent COC use: Continuous use is more effective than cyclic regimens for endometriosis pain
• Premature escalation to GnRH agonists: Ensure adequate trial of first-line therapies before escalating
• Treating with NSAIDs alone: This provides inadequate symptom control for endometriosis-related pain

The evidence consistently supports that hormonal medical therapy should be the initial approach, with treatment selection individualized based on contraceptive needs, side effect profile, cost, and patient preference among the first-line options 1, 2, 7.